Pharma

An international Biopharma manufacturer company retained RegAgile to find out if the Biopharma product manufactured using the active ingredients sourced from Israel can be registered or imported for sale in MENA markets.
What will be the potential alternative solutions for such products.

In depth regulatory environment was monitored and local regulations around import/registration as well as trade policies were reviewed.
A detailed assessment was provided for 11 MENA markets highlighting the risks and challenges using source of API from Israel.
Out of 11 markets only 4 markets were feasible to register the product with such sources from Israel considering the ongoing Gaza–Israel conflict in MENA region.
The detailed opportunity assessment was provided with alternative solutions such as NPS/personal use etc.  where applicable to enable the market access.